天坛生物直线涨停，科拓生物、南模生物、赛伦生物涨超10%，沃森生物、安旭生物等跟涨。 (本文来自第一财经) ...

MACD金叉信号形成，这些股涨势不错！ 据北京日报，中国疾控中心艾防中心等团队完成我国首个复制型天坛痘苗载体艾滋病疫苗I期临床试 验。该研究创新性采用曾用于消灭天花的"天坛株"痘苗病毒为载体，试验验证了该方案的安全性且能激 发有效免疫反应。这标志着我国在艾滋病疫苗研发领域取得重要进展。 受此影响，A股市场生物医药股拉升，其中，南模生物、赛伦生物涨超14%，天坛生物10CM涨停，之 江生物、沃森生物、仁度生物、安旭生物等跟涨。 ...

Group 1 - The A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting a 10% limit up [1] - The China CDC and other teams completed the first Phase I clinical trial of a replicative Tian Tan smallpox vaccine-based HIV vaccine, marking a significant advancement in HIV vaccine research in China [1] - The innovative approach utilized the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, to verify the safety and effective immune response of the vaccine [1]

Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained 44 new authorized patents, including 13 invention patents, bringing the total to 305 authorized patents, of which 43 are invention patents [1] Financial Performance - As of the first quarter of 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The company's gross profit margin stands at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 33.53, compared to the industry average of 54.56 and the industry median of 37.54 [2] - The company's total market capitalization is 5.235 billion yuan [1][2] - As of the first quarter of 2025, two institutions hold shares in Anxu Bio, with a total of 172,000 shares valued at 0.07 million yuan [1]

Core Viewpoint - The company announced a cash dividend distribution of 0.8 yuan per share for the fiscal year 2024, totaling approximately 101.67 million yuan for all shareholders [2][4]. Summary by Relevant Sections Dividend Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on May 22, 2025 [2]. - The total share capital before the distribution is 127,082,805 shares, with a total cash dividend of 101,666,244 yuan [4]. Distribution Objects - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the dividend record date [3]. Implementation Method - The dividends for unrestricted circulating shares will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [4]. - Shareholders who have completed designated trading can receive their cash dividends on the distribution date at their designated securities business department [4]. Taxation on Dividends - For individual shareholders holding unrestricted circulating shares for over one year, the cash dividend of 0.8 yuan per share is exempt from personal income tax [8]. - For shares held for one year or less, the tax will be calculated upon the transfer of shares, with a maximum effective tax rate of 20% for shares held for one month or less [8]. - For limited circulating shares, the tax treatment varies, with a post-tax dividend of 0.72 yuan per share for certain categories of shareholders [9][10]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's securities department at 0571-85391552 [10].

Core Points - The company announced a cash dividend distribution of 0.8 RMB per share, totaling 101,666,244 RMB based on a total share capital of 127,082,805 shares [1] - The dividend distribution plan was approved at the annual general meeting held on May 22, 2025 [1] - The cash dividend will be distributed to shareholders registered by the end of the trading day on the record date [1] Dividend Distribution Details - The cash dividend of 0.8 RMB per share is inclusive of tax [1] - The distribution will be managed by China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1] - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [1] Tax Implications - For individual shareholders holding unrestricted shares for over one year, the dividend income is exempt from individual income tax [3] - For shares held for less than one year, the tax treatment varies: 20% tax for holdings of one month or less, and 10% tax for holdings between one month and one year [3] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.72 RMB per share [5] - Hong Kong investors will also receive a net dividend of 0.72 RMB per share after a 10% tax withholding [5]

证券代码：688075 证券简称：安旭生物 公告编号：2025-015 杭州安旭生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.8元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/17 | 2025/7/18 | 2025/7/18 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 22 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本127,082,805股为基数，每股派发现 金红利0.8元（含税），共计派发现金红利101,666,244.00元。 三、相关日期 | 股权登记日 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anxu Biotech, indicating a decline in revenue and profit while comparing its valuation metrics to industry averages [1][2] - Anxu Biotech's closing stock price is 39.22 yuan, with a rolling PE ratio of 31.92, marking a new low in 22 days, and a total market capitalization of 4.984 billion yuan [1] - The company ranks 70th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1][2] Group 2 - As of the first quarter of 2025, six institutions hold shares in Anxu Biotech, with a total of 50.3836 million shares valued at 1.998 billion yuan [1] - Anxu Biotech specializes in the research, production, and sales of POCT reagents and instruments, having received multiple certifications including EU CE, Canadian, and Australian certifications [1] - The latest financial report for the first quarter of 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.0296 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]

Fundraising Overview - The company, Hangzhou Anxu Biotechnology Co., Ltd., successfully raised a total of RMB 1,200.30 million by issuing 15,333,400 shares at a price of RMB 78.28 per share, with a net amount of RMB 1,055.85 million after deducting various fees [1] - The funds have been deposited into a special account approved by the board of directors, and a tripartite supervision agreement has been signed with the sponsor and the bank [1] Fund Management - The company has established a fundraising management system in accordance with regulatory requirements to ensure effective use and management of the raised funds [2] - Strict approval processes are in place for the use of funds, ensuring that they are used for designated projects [2] Supervision Agreements - Multiple tripartite and quadripartite supervision agreements have been signed with various banks to regulate the management of the raised funds, with all agreements functioning normally as of December 31, 2024 [3][4][5] Account Closure - Due to the completion of certain fundraising projects, the company has decided to close specific fundraising accounts to streamline management and reduce costs [5] - The closure of these accounts has been completed, and the corresponding supervision agreements have been terminated [5]

证券代码：688075 证券简称：安旭生物 公告编号：2025-014 杭州安旭生物科技股份有限公司 关于部分募集资金账户注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"安旭生物"或"公司"）董事会首次 公开发行股票募集资金按照相关法律、法规和规范性文件的规定在银行开立了募集资 金专项账户。近日，公司办理完成部分募集资金专用账户的注销手续，现将具体情况 公告如下： 一、 募集资金基本情况 根据中国证券监督管理委员会于 2021 年 9 月 28 日出具的《关于同意杭州安旭生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3138 号），公 司获准向社会公开发行人民币普通股 15,333,400 股，每股发行价格为人民币 78.28 元， 募集资金总额为 120,029.86 万元；扣除承销及保荐费用、发行登记费以及其他交易费 用共计 14,445.23 万元（不含增值税金额）后，募集资金净额为 105,584.63 万元，上述 资金已全部到位，经信永 ...